HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.

AbstractPURPOSE:
To evaluate the toxicity, antitumoral effectiveness, and immunogenicity of repeated vaccinations with ALVAC miniMAGE-1/3, a recombinant canarypox virus containing a minigene encoding antigenic peptides MAGE-3(168-176) and MAGE-1(161-169), which are presented by HLA-A1 and B35 on tumor cells and can be recognized by cytolytic T lymphocytes (CTLs).
MATERIALS AND METHODS:
The vaccination schedule comprised four sequential injections of the recombinant virus, followed by three booster vaccinations with the MAGE-3(168-176) and MAGE-1(161-169) peptides. The vaccines were administered, both intradermally and subcutaneously, at 3-week intervals.
RESULTS:
Forty patients with advanced cancer were treated, including 37 melanoma patients. The vaccines were generally well tolerated with moderate adverse events, consisting mainly of transient inflammatory reactions at the virus injection sites. Among the 30 melanoma patients assessable for tumor response, a partial response was observed in one patient, and disease stabilization in two others. The remaining patients had progressive disease. Among the patients with stable or progressive disease, five showed evidence of tumor regression. A CTL response against the MAGE-3 vaccine antigen was detected in three of four patients with tumor regression, and in only one of 11 patients without regression.
CONCLUSION:
Repeated vaccination with ALVAC miniMAGE-1/3 is associated with tumor regression and with a detectable CTL response in a minority of melanoma patients. There is a significant correlation between tumor regression and CTL response. The contribution of vaccine-induced CTL in the tumor regression process is discussed in view of the immunologic events that could be analyzed in detail in one patient.
AuthorsNicolas van Baren, Marie-Claude Bonnet, Brigitte Dréno, Amir Khammari, Thierry Dorval, Sophie Piperno-Neumann, Danielle Liénard, Daniel Speiser, Marie Marchand, Vincent G Brichard, Bernard Escudier, Sylvie Négrier, Pierre-Yves Dietrich, Dominique Maraninchi, Susanne Osanto, Ralf G Meyer, Gerd Ritter, Philippe Moingeon, Jim Tartaglia, Pierre van der Bruggen, Pierre G Coulie, Thierry Boon
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 23 Issue 35 Pg. 9008-21 (Dec 10 2005) ISSN: 0732-183X [Print] United States
PMID16061912 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • ALVAC vaccine
  • Antigens, Neoplasm
  • Cancer Vaccines
  • MAGEA1 protein, human
  • MAGEA3 protein, human
  • Melanoma-Specific Antigens
  • Neoplasm Proteins
  • Viral Vaccines
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, Neoplasm (immunology)
  • Canarypox virus (immunology)
  • Cancer Vaccines (immunology)
  • Disease Progression
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Male
  • Melanoma (immunology, therapy)
  • Melanoma-Specific Antigens
  • Middle Aged
  • Neoplasm Proteins (immunology)
  • T-Lymphocytes, Cytotoxic (immunology)
  • Treatment Outcome
  • Viral Vaccines (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: